Recognizing this concern regarding toxicity, we sought to identify whether different cancers show enhanced susceptibility to bromodomain or HAT domain inhibition, for the purposes of nominating specific tumors for further exploration of specific types of EP300/CBP inhibitors. This evidence concerns the gene EP300 and cancer.